Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · OCULAR THERAPEUTIX, INC (OCUL)

Ocular Therapeutix adds director Riad Sherif; Seung Suh Hong to resign from board Dec. 31

Neutral Impact 2 of 5 leadership

Ocular Therapeutix's board elected Riad Sherif, M.D., as a director effective November 6, 2026, and director Seung Suh Hong gave notice of his resignation effective December 31, 2026. The filing says Hong's resignation is not due to any disagreement with the board or management, and Sherif receives the same non-employee director compensation as other outside directors.

Key points

  • Riad Sherif, M.D., 58, elected to the board effective November 6, 2026 as a Class I director, serving until the 2027 annual meeting
  • Sherif received an option for 88,000 shares at $6.60 per share and a restricted stock unit award for 28,000 shares, vesting annually over three years
  • Sherif is CEO and a board member of Oculis Holding AG; he previously held roles at Novartis and Alcon
  • Seung Suh Hong, Ph.D., resigns from the board effective December 31, 2026

The filing

CompanyOCULAR THERAPEUTIX, INC (OCUL)
Form8-K, current report
Filed with the SECNov 9, 2026, 7:28 AM ET
Accession number0001104659-26-124159

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:35 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.